中国临床药理学杂志2023，Vol.39Issue(23)：3375-3378,4.DOI:10.13699/j.cnki.1001-6821.2023.23.007
贝伐珠单抗联合白蛋白紫杉醇和卡铂治疗晚期非小细胞肺癌患者的临床研究
Clinical trial of bevacizumab combined with albumin paclitaxel and carboplatin in the treatment of patients with advanced non-small cell lung cancer
摘要
Abstract
Objective To observe the clinical efficacy and safety of bevacizumab combined with paclitaxel for injection(albumin bound)and carboplatin injection in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods The patients with advanced NSCLC were divided into control and treatment groups.The control group was given 130 mg·kg-1·m-2paclitaxel,intravenous infusion for 40 min,on the day 1 and 8+300 mg·m-2 carboplatin,intravenous infusion on the day 1.On the basis of the control group,the treatment group was combined with 7.5 mg·kg-1·m-2 bevacizumab,intravenous infusion,on the day 1.Two groups were treated for 4 cycles with 3 weeks per cycle.The clinical efficacy,levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),CA199,vascular endothelial growth factor(VEGF)and connective tissue growth factor(CTGF),1-year cumulative survival rate and adverse drug reactions were compared between two groups.Results In the treatment group,45 cases were enrolled,4 cases dropped out,and 41 cases were included in the analysis.In the control group,47 cases were enrolled,6 cases were dropped out,and 41 cases were finally included in the analysis.After treatment,the CEA levels of treatment and control groups were(18.51±3.52)and(24.31±3.89)ng·mL-1;the CA125 levels were(17.68±3.62)and(25.62±4.21)ng·mL-1;the CA199 levels were(30.24±5.99)and(45.23±7.25)ng·mL-1;the VEGF levels were(126.34±14.21)and(170.25±18.69)ng·L-1;the CTGF levels were(1 400.14±199.21)and(1 542.31±210.35)ng·L-1,and the differences were statistically significant(all P＜0.05).The 1-year cumulative survival rates of treatment and control groups were 70.73％(29 cases/41 cases)and 48.78％(20 cases/41 cases)with significant difference(P＜0.05).The adverse drug reactions of two groups were anorexia,gastrointestinal reaction,bone marrow suppression,liver and kidney function impairment and proteinuria.The total incidences of adverse drug reactions in the treatment and control groups were 39.02％and 34.15％without significant difference(P＞0.05).Conclusion Bevacizumab combined with paclitaxel(albumin bound)injection and carboplatin injection has a definite clinical efficacy in the treatment of patients with advanced NSCLC,which can significantly improve the survival rate,and without increasing the incidence of adverse drug reactions.关键词
贝伐珠单抗/注射用紫杉醇(白蛋白结合型)/卡铂注射液/非小细胞肺癌/临床疗效/安全性评价Key words
bevacizumab/paclitaxel injection(albumin bound)/carboplatin injection/non-small cell lung cancer/clinical efficacy/safety evaluation分类
医药卫生引用本文复制引用
裴士杰,邵强,叶永青,钱小军..贝伐珠单抗联合白蛋白紫杉醇和卡铂治疗晚期非小细胞肺癌患者的临床研究[J].中国临床药理学杂志,2023,39(23):3375-3378,4.基金项目
华南肿瘤学国家重点实验室开放课题基金资助项目(HN2020-03) （HN2020-03）
